RetinAI Joins Ryan Initiative for Macular Research AMD Consortium

RetinAI Medical announced that they are now joining the Ryan Initiative for Macular Research (RIMR) Age-related Macular Degeneration (AMD) Imaging Consortium, a non-profit group of physicians, researchers, and industry partners working together to define optimal biomarkers and endpoints in AMD.

RetinAI develops clinical and imaging data management software and advanced analytics using artificial intelligence (AI).

According to the company, RIMR members from around the world will now be able to connect through RetinAI Discovery, the company’s cloud-based platform, to facilitate a frictionless collaboration and derive insights on global AMD datasets, helping to advance research in this disease that is a leading cause of blindness in older individuals.

As a member of the consortium, RetinAI will leverage its digital health technologies to support RIMR’s international network of leading experts in AMD to aggregate and analyze at-scale research and real-world clinical and imaging data. The result will be the generation of a highly diverse database and analysis using AI to help address leading research questions of AMD, such as differences among ethnic groups, stated the company.

“We’re excited about working with RetinAI as a member of the consortium,” commented SriniVas Sadda, MD, Executive Committee Chair for RIMR, in RetinAI’s press release. “RetinAI’s focus on digital health technologies and connectivity in ophthalmology will enable us to build a highly diverse database in AMD, providing the enriched insights to advance our understanding of AMD to drive our goal for finding a cure in AMD.” Dr. Sadda is Director of the AI Laboratory at Doheny Eye Institute and Professor, David Geffen School of Medicine at UCLA in Los Angeles, California.

RetinAI CEO Carlos Ciller, PhD, added, “By being a member of RIMR, we are setting the foundation to connect leading AMD experts from around the world to help advance their important biomarker-led research. We are thrilled to be a part of the consortium and help to facilitate cutting-edge research with a shared goal of improving patient care.”